Met Life Investment Management, LLC Morphic Holding, Inc. Transaction History

Met Life Investment Management, LLC

$17.1 Billion
Q3 2024

37 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$26.12 - $34.07 $95,729 - $124,866	3,665 Added 18.88%	23,077 $786,000
Q1 2024 May 14, 2024	BUY	$26.64 - $40.31 $517,135 - $782,497	19,412 New	19,412 $683,000
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $25,097 - $38,998	1,258 Added 6.93%	19,412 $560,000
Q3 2023 May 09, 2024	BUY	$21.33 - $59.42 $98,309 - $273,866	4,609 Added 34.03%	18,154 $415,000
Q3 2023 Apr 29, 2024	BUY	$21.33 - $59.42 $44,920 - $125,138	2,106 Added 13.12%	18,154 $415,000
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $44,920 - $125,138	2,106 Added 13.12%	18,154 $415,000
Q2 2023 Apr 29, 2024	BUY	$34.33 - $62.11 $550,927 - $996,741	16,048 New	16,048 $920,000
Q2 2023 Aug 10, 2023	BUY	$34.33 - $62.11 $85,927 - $155,461	2,503 Added 18.48%	16,048 $920,000
Q1 2023 May 09, 2024	BUY	$26.01 - $48.69 $352,305 - $659,506	13,545 New	13,545 $510 Million
Q1 2023 May 15, 2023	BUY	$26.01 - $48.69 $9,363 - $17,528	360 Added 2.73%	13,545 $509,000
Q4 2022 May 10, 2024	SELL	$24.14 - $30.37 $38,551 - $48,500	-1,597 Reduced 10.8%	13,185 $352,000
Q4 2022 Jun 14, 2023	SELL	$24.14 - $30.37 $8,690 - $10,933	-360 Reduced 2.66%	13,185 $352,000
Q4 2022 Mar 22, 2023	SELL	$24.14 - $30.37 $38,551 - $48,500	-1,597 Reduced 10.8%	13,185 $352,000
Q4 2022 Feb 15, 2023	SELL	$24.14 - $30.37 $38,551 - $48,500	-1,597 Reduced 10.8%	13,185 $352,000
Q3 2022 May 10, 2024	BUY	$22.23 - $33.37 $58,109 - $87,229	2,614 Added 21.48%	14,782 $418,000
Q3 2022 Jun 14, 2023	BUY	$22.23 - $33.37 $27,498 - $41,278	1,237 Added 9.13%	14,782 $418,000
Q3 2022 Mar 22, 2023	BUY	$22.23 - $33.37 $58,109 - $87,229	2,614 Added 21.48%	14,782 $418,000
Q3 2022 Nov 14, 2022	BUY	$22.23 - $33.37 $58,109 - $87,229	2,614 Added 21.48%	14,782 $418,000
Q2 2022 Jun 20, 2023	SELL	$19.74 - $43.01 $27,181 - $59,224	-1,377 Reduced 10.17%	12,168 $264,000
Q1 2022 May 10, 2024	BUY	$36.25 - $52.02 $441,090 - $632,979	12,168 New	12,168 $488,000
Q1 2022 Jun 20, 2023	SELL	$36.25 - $52.02 $49,916 - $71,631	-1,377 Reduced 10.17%	12,168 $488,000
Q1 2022 Mar 22, 2023	BUY	$36.25 - $52.02 $162,798 - $233,621	4,491 Added 58.5%	12,168 $488,000
Q1 2022 May 12, 2022	BUY	$36.25 - $52.02 $162,798 - $233,621	4,491 Added 58.5%	12,168 $489,000
Q4 2021 Jun 21, 2023	SELL	$43.27 - $65.72 $253,908 - $385,644	-5,868 Reduced 43.32%	7,677 $363,000
Q3 2021 Jun 21, 2023	SELL	$53.61 - $67.5 $314,583 - $396,090	-5,868 Reduced 43.32%	7,677 $434,000
Q2 2021 May 17, 2024	BUY	$45.13 - $64.99 $47,251 - $68,044	1,047 Added 15.79%	7,677 $440,000
Q2 2021 Jun 21, 2023	SELL	$45.13 - $64.99 $264,822 - $381,361	-5,868 Reduced 43.32%	7,677 $440,000
Q2 2021 Mar 22, 2023	BUY	$45.13 - $64.99 $47,251 - $68,044	1,047 Added 15.79%	7,677 $440,000
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $47,251 - $68,044	1,047 Added 15.79%	7,677 $441,000
Q1 2021 May 17, 2024	SELL	$29.77 - $84.85 $380,520 - $1.08 Million	-12,782 Reduced 65.85%	6,630 $419,000
Q1 2021 Jun 26, 2023	SELL	$29.77 - $84.85 $205,859 - $586,737	-6,915 Reduced 51.05%	6,630 $420 Million
Q4 2020 Jun 22, 2023	SELL	$25.66 - $34.55 $177,438 - $238,913	-6,915 Reduced 51.05%	6,630 $222,000
Q3 2020 Jun 26, 2023	SELL	$22.51 - $30.11 $155,656 - $208,210	-6,915 Reduced 51.05%	6,630 $181,000
Q2 2020 May 24, 2024	SELL	$12.65 - $29.57 $161,692 - $377,963	-12,782 Reduced 65.85%	6,630 $179 Million
Q2 2020 Jun 26, 2023	SELL	$12.65 - $29.57 $87,474 - $204,476	-6,915 Reduced 51.05%	6,630 $179,000
Q2 2020 Mar 22, 2023	SELL	$12.65 - $29.57 $82,920 - $193,831	-6,555 Reduced 49.72%	6,630 $179,000
Q2 2020 Aug 14, 2020	BUY	$12.65 - $29.57 $83,869 - $196,049	6,630 New	6,630 $179,000

Others Institutions Holding MORF

# of Institutions

Shares Held

4.7M

Call Options Held

Put Options Held

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Account